Edition:
United Kingdom

People: Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

21.48USD
18 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$21.48
Open
$21.36
Day's High
$21.72
Day's Low
$21.03
Volume
315,085
Avg. Vol
530,687
52-wk High
$45.12
52-wk Low
$19.37

Stejbach, Mark 

Mr. Mark P. Stejbach is a Senior Vice President, Chief Commercial Officer of Alkermes PLC. Prior to assuming his current position, Mr. Stejbach served at Tengion, Inc. from 2008 to 2012, most recently as its Chief Commercial Officer. He previously held senior positions at Merck and Biogen Idec Inc. and has over 30 years of experience in biotech and pharmaceutical marketing, sales, managed care and finance. Mr. Stejbach currently serves on the board of directors for Flexion Therapeutics, a publicly traded pharmaceutical company. He previously served on the charitable board of the Commonwealth National Fund from 2003 through 2011 and has served on the Advisory Board of the Center for Value-Based Insurance Design since 2009.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

9,380,490

James Frates

2,828,540

Elliot Ehrich

3,547,020

Iain Brown

--

David Gaffin

--

Michael Landine

--
As Of  31 Dec 2017